Drug Trial Radar · NCT03640481
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy
Last checked: Nov 20, 2026Latest source record: Dec 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
159
Actual
Start
Oct 11, 2018
Primary completion
Dec 11, 2023
Study completion Dec 11, 2023
Sponsor
- Lead sponsor
- Kadmon, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 21, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy
Conditions
- Chronic Graft-versus-host-disease
Interventions
Belumosudil (KD025)Drug
Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 40.5 months for adult arms and 27.6 months for adolescent arms)
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Phoenix Childrens Hospital Site Number : 154
Phoenix, Arizona
University of Arizona - Cancer Center Site Number : 122
Tucson, Arizona
City of Hope Medical Center Site Number : 050
Duarte, California
University of California, Los Angeles (UCLA) - Medical Center Site Number : 104
Los Angeles, California
University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center Site Number : 058
San Francisco, California
Stanford Cancer Center Site Number : 108
Stanford, California
Colorado Blood Cancer Institute Site Number : 098
Denver, Colorado
University of Miami - Sylvester Cancer Center Site Number : 097
Miami, Florida
Moffitt Site Number : 102
Tampa, Florida
Emory University School of Medicine Site Number : 100
Atlanta, Georgia
Augusta University Medical Center Site Number : 093
Augusta, Georgia
University of Illinois at Chicago Site Number : 139
Chicago, Illinois
University of Iowa Site Number : 126
Iowa City, Iowa
University of Kansas Cancer Center Site Number : 105
Fairway, Kansas
Center for Cancer Research National Cancer Institute Site Number : 107
Bethesda, Maryland
Massachusetts General Hospital Site Number : 002
Boston, Massachusetts
Dana-Farber Cancer Institute Site Number : 004
Boston, Massachusetts
CS Mott Children's Hospital Site Number : 157
Ann Arbor, Michigan
Barbara Ann Karmanos Cancer Institute-4100 John R St Site Number : 094
Detroit, Michigan
University of Minnesota Site Number : 051
Minneapolis, Minnesota
Washington University School of Medicine Site Number : 125
St Louis, Missouri
University of Rochester Site Number : 106
Rochester, New York
Wake Forest Site Number : 123
Winston-Salem, North Carolina
The Cleveland Clinic Foundation Site Number : 041
Cleveland, Ohio
James Cancer Hospital & Wexner Medical Center at the Ohio State University Comprehensive Cancer Center Site Number : 103
Columbus, Ohio
Oregon Health & Science University (OHSU) Site Number : 095
Portland, Oregon
University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center Site Number : 132
Pittsburgh, Pennsylvania
Sarah Cannon and HCA Research Institute Site Number : 007
Nashville, Tennessee
Vanderbilt University Medical Center Site Number : 063
Nashville, Tennessee
South Austin Medical Center Site Number : 091
Austin, Texas
MD Anderson Cancer Center Site Number : 057
Houston, Texas
Texas Transplant Institute Site Number : 079
San Antonio, Texas
Fred Hutchinson Cancer Research Center Site Number : 052
Seattle, Washington
University of Wisconsin - Carbone Cancer Center Site Number : 135
Madison, Wisconsin
Froedtert Hospital and the Medical College of Wisconsin Site Number : 101
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.